Tonix Pharmaceuticals Holding Corp. (TNXP) stock
TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3084% below fair value
$3.01−0.23 (-7.10%)
Close on Nov 13, 2026Market cap $51.62MP/E –Yield –
Tonix Pharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
Tonix Pharmaceuticals's operating margin for the twelve months ending Sep 30, 2026 was -436.3%. For fiscal 2025 it was -959.1%, against -1354.3% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -959.1% | +395.2 |
| FY2024 | Dec 31, 2024 | -1354.3% | +169.7 |
| FY2023 | Dec 31, 2023 | -1523.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -321.6% | +683.4 |
| Q2 FY2026 | Jun 30, 2026 | -314.1% | +1102.2 |
| Q1 FY2026 | Mar 31, 2026 | -603.9% | +57.0 |
| Q4 FY2025 | Dec 31, 2025 | -895.8% | −25.2 |
| Q3 FY2025 | Sep 30, 2025 | -1005.1% | −453.9 |
| Q2 FY2025 | Jun 30, 2025 | -1416.2% | +2085.4 |
| Q1 FY2025 | Mar 31, 2025 | -660.9% | +199.3 |
| Q4 FY2024 | Dec 31, 2024 | -870.6% | −147.5 |
| Q3 FY2024 | Sep 30, 2024 | -551.2% | +154.4 |
| Q2 FY2024 | Jun 30, 2024 | -3501.6% | – |
| Q1 FY2024 | Mar 31, 2024 | -860.2% | – |
| Q4 FY2023 | Dec 31, 2023 | -723.2% | – |
| Q3 FY2023 | Sep 30, 2023 | -705.6% | – |
See a number that looks wrong?